AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29987559 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Education group (N=55)
Number of subjects: 165
Study 29987559 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition (N=56)
Number of subjects: 165
Study 28028552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical prophylaxis (MP)
Number of subjects: 603
Study 28028552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological prophylaxis
Number of subjects: 603
Study 28028552 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE development
Number of subjects: 603
Study 28028552 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 603
Study 28028552 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient weight
Number of subjects: 603
Study 28028552 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI severity
Number of subjects: 603
Study 28028552 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE development and mortality
Number of subjects: 603
Study 25882778 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg every 12h for 4 weeks
Number of subjects: 90
Study 25882778 — intervention group
Group type: COMPARATOR
Intervention: Control (no tetracycline)
Number of subjects: 90
Study 23527502 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjectively pleasant activities
Number of subjects: 41
Study 23527502 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of depression
Number of subjects: 41
Study 22126919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty
Number of subjects: 22
Study 22126919 — intervention group
Group type: COMPARATOR
Intervention: Uncemented hemiarthroplasty
Number of subjects: 22
Study 19398277 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (35 mg)
Number of subjects: 44
Study 19398277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 17362946 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of bed rest after embryo transfer
Number of subjects: 164
Study 17362946 — intervention group
Group type: COMPARATOR
Intervention: Immediate discharge from the clinic
Number of subjects: 164
Study 15470487 — intervention group
Group type: EXPERIMENTAL
Intervention: AB killer cell immunoglobulin-like receptor (KIR) phenotype in leukemic patients
Number of subjects: 244
Study 15470487 — intervention group
Group type: COMPARATOR
Intervention: AB killer cell immunoglobulin-like receptor (KIR) phenotype in healthy controls
Number of subjects: 244
Study 15470487 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory KIR2DL2 in leukemic patients
Number of subjects: 244
Study 15470487 — intervention group
Group type: EXPERIMENTAL
Intervention: KIR phenotypes AB1 and AB9
Number of subjects: 244
Study 11467911 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (intravenous injection)
Number of subjects: 13
Study 11467911 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (intravenous injection)
Number of subjects: 13
Study 9601623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 457
Study 9601623 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 457
Study 9601623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 7976460 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment program (details not specified)
Number of subjects: 11
Study 7976460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive test battery (backward masking)
Number of subjects: 11
Study 7976460 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication Conflict Situation and Camberwell Family Interview (for parents)
Number of subjects: 11
Study 3371882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hypertonic glucose (900 mOsmoles per liter) at 2 ml per min
Number of subjects: 16
Study 3371882 — intervention group
Group type: COMPARATOR
Intervention: Mannitol (n = 4)
Number of subjects: 16
Study 3371882 — intervention group
Group type: COMPARATOR
Intervention: Saline (n = 4)
Number of subjects: 16
Study 31863865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib ECS tablets (11 mg and 22 mg)
Number of subjects: 0
Study 31863865 — intervention group
Group type: COMPARATOR
Intervention: 5 mg immediate-release formulation tablet
Number of subjects: 0
Study 30181096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg once daily for 7-10 days
Number of subjects: 527
Study 30181096 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once daily for 7-10 days
Number of subjects: 527
Study 30181096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Number of subjects: 527
Study 30181096 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 527
Study 27389435 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-6 mm implant
Number of subjects: 56
Study 27389435 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-8 mm implant with OSFE
Number of subjects: 56
Study 27389435 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-10 mm implant with OSFE
Number of subjects: 56
Study 26354859 — intervention group
Group type: EXPERIMENTAL
Intervention: SPEACS communication strategies
Number of subjects: 1440
Study 25445508 — intervention group
Group type: EXPERIMENTAL
Intervention: Too Good for Drugs (TGFD) prevention program
Number of subjects: 10762
Study 25445508 — intervention group
Group type: COMPARATOR
Intervention: Control group (6th graders not participating in TGFD)
Number of subjects: 10762
Study 20686007 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider origin bacterial transmission to the IV stopcock set
Number of subjects: 164
Study 20686007 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider origin bacterial transmission to the anesthesia environment
Number of subjects: 164
Study 20686007 — intervention group
Group type: COMPARATOR
Intervention: Independent predictors of bacterial transmission events
Number of subjects: 164
Study 19244691 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cannulation
Number of subjects: 120
Study 19244691 — intervention group
Group type: COMPARATOR
Intervention: Retrograde cannulation
Number of subjects: 120
Study 16776793 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific computerized prescribing alerts
Number of subjects: 50924
Study 16776793 — intervention group
Group type: EXPERIMENTAL
Intervention: Group academic detailing
Number of subjects: 50924
Study 16776793 — intervention group
Group type: COMPARATOR
Intervention: Drug-specific computerized prescribing alerts (baseline)
Number of subjects: 50924
Study 14687170 — intervention group
Group type: EXPERIMENTAL
Intervention: OAF (Omeprazole 20 mg b.d., Amoxicillin 1000 mg b.d., Furazolidone 100 mg b.d. for 14 days)
Number of subjects: 150
Study 14687170 — intervention group
Group type: EXPERIMENTAL
Intervention: OABF1 (Omeprazole 20 mg b.d., Amoxicillin 1000 mg b.d., Furazolidone 100 mg b.d., Bismuth Subcitrate 240 mg b.d. for 14 days)
Number of subjects: 150
Study 14687170 — intervention group
Group type: EXPERIMENTAL
Intervention: OABF2 (Omeprazole 20 mg b.d., Amoxicillin 1000 mg b.d., Furazolidone 200 mg b.d., Bismuth Subcitrate 240 mg b.d. for 14 days)
Number of subjects: 150
Study 11374675 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy
Number of subjects: 276
Study 11374675 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term omeprazole therapy
Number of subjects: 276
Study 9291702 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine administration
Number of subjects: 36
Study 9291702 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine administration
Number of subjects: 36
Study 9291702 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated serum creatinine
Number of subjects: 36
Study 9291702 — intervention group
Group type: COMPARATOR
Intervention: Patients with normal serum creatinine
Number of subjects: 36
Study 9291702 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with opioid-induced adverse effects
Number of subjects: 36
Study 9291702 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated plasma M3G and M6G concentrations
Number of subjects: 36
Study 8404995 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion at rates of 6 to 40 mumol kg‐1 min‐1
Number of subjects: 17
Study 8404995 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate infusion (control)
Number of subjects: 17
Study 8404995 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall rates of lactate appearance during lactate infusions
Number of subjects: 17
Study 3951079 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidential feedback on individual rates of use compared with peers (cost feedback)
Number of subjects: 0
Study 3951079 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on rates of abnormal test results (yield feedback)
Number of subjects: 0
Study 3951079 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-specific education
Number of subjects: 0
Study 29369240 — intervention group
Group type: EXPERIMENTAL
Intervention: CapsoCam SV‐1
Number of subjects: 153
Study 29369240 — intervention group
Group type: COMPARATOR
Intervention: PillCam SB 3
Number of subjects: 153
Study 29779815 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral formula with prebiotic content (EFPC)
Number of subjects: 46
Study 29779815 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral formula (SEF)
Number of subjects: 46
Study 27348913 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at the acupoints selected from the affected meridians and heavy moxibustion at painful points, applied once every two days, three times a week, for 4 weeks.
Number of subjects: 32
Study 27348913 — intervention group
Group type: COMPARATOR
Intervention: Medication group with tramadol sustained release tablets and amitriptyline, prescribed once a day for 4 weeks.
Number of subjects: 32
Study 25059532 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (1mg)
Number of subjects: 15
Study 25059532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 22687580 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe 800-1600 mg/d for 6 weeks
Number of subjects: 73
Study 22687580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 22687580 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe
Number of subjects: 73
Study 21179684 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol chewing gums
Number of subjects: 30
Study 21179684 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gums
Number of subjects: 30
Study 21179684 — intervention group
Group type: COMPARATOR
Intervention: Gum base chewing gums
Number of subjects: 30
Study 18096050 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Number of subjects: 166
Study 18096050 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (placement of local anesthesia near the fracture)
Number of subjects: 166
Study 15764352 — intervention group
Group type: EXPERIMENTAL
Intervention: Legs covered with towels during DHT (24 treatments)
Number of subjects: 14
Study 15764352 — intervention group
Group type: COMPARATOR
Intervention: Legs not covered with towels during DHT (27 treatments)
Number of subjects: 14
Study 12062853 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 51
Study 12062853 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of metformin
Number of subjects: 51
Study 9458021 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5 g twice daily with intravenous corticosteroids (5 mg/kg/day for 5 days followed by oral taper)
Number of subjects: 221
Study 9458021 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 1-2 mg/kg/day with intravenous corticosteroids (5 mg/kg/day for 5 days followed by oral taper)
Number of subjects: 221
Study 8574509 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of hymecromone
Number of subjects: 20
Study 8574509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2676941 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 40
Study 2676941 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate potassium (Augmentin)
Number of subjects: 40
Study 80577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet irradiation
Number of subjects: 0
Study 80577 — intervention group
Group type: EXPERIMENTAL
Intervention: Background irradiation
Number of subjects: 0
Study 31959263 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score based on four of the six SNP associated with low 25(OH)D
Number of subjects: 699
Study 31959263 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR SNP
Number of subjects: 699
Study 31959263 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score
Number of subjects: 699
Study 30777024 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-DNA-positive group
Number of subjects: 0
Study 30777024 — intervention group
Group type: COMPARATOR
Intervention: HBV-DNA-negative group
Number of subjects: 0
Study 29351537 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery regime (no Redon drain, intensified analgesia, immediate mobilization)
Number of subjects: 194
Study 29351537 — intervention group
Group type: COMPARATOR
Intervention: Conventional regime (with Redon drain, no femoral nerve block, no immediate mobilization)
Number of subjects: 194
Study 29351537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Enhanced and Conventional)
Number of subjects: 194
Study 25422883 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-601,927 2 mg twice daily
Number of subjects: 0
Study 25422883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23312429 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with MBSCT and enhanced medication management
Number of subjects: 0
Study 23312429 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with MBSCT and enhanced medication management
Number of subjects: 0
Study 23312429 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone with enhanced medication management only
Number of subjects: 0
Study 23312429 — intervention group
Group type: COMPARATOR
Intervention: Placebo with enhanced medication management only
Number of subjects: 0
Study 20716475 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle Aspiration (NA)
Number of subjects: 48
Study 20716475 — intervention group
Group type: COMPARATOR
Intervention: Minichest Tube (MCT)
Number of subjects: 48
Study 19272057 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine therapy
Number of subjects: 9
Study 16732777 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding counseling by trained midwives and nurses
Number of subjects: 540
Study 15306152 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antiphospholipid antibodies
Number of subjects: 0
Study 15306152 — intervention group
Group type: EXPERIMENTAL
Intervention: Human sera containing antiphospholipid antibodies
Number of subjects: 0
Study 15306152 — intervention group
Group type: COMPARATOR
Intervention: Resting endothelial cells
Number of subjects: 0
Study 15306152 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated endothelial cells
Number of subjects: 0
Study 11170325 — intervention group
Group type: EXPERIMENTAL
Intervention: Right radial approach
Number of subjects: 210
Study 11170325 — intervention group
Group type: EXPERIMENTAL
Intervention: Left radial approach
Number of subjects: 210
Study 11170325 — intervention group
Group type: COMPARATOR
Intervention: Femoral approach
Number of subjects: 210
Study 11170325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both radial approaches
Number of subjects: 210
Study 11170325 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial approach
Number of subjects: 210
Study 11170325 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 210
Study 9421239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent slow‐release sodium fluoride (SRNaF) and continuous calcium citrate
Number of subjects: 33
Study 8431313 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. morphine
Number of subjects: 32
Study 8431313 — intervention group
Group type: COMPARATOR
Intervention: extradural bupivacaine
Number of subjects: 32
Study 8431313 — intervention group
Group type: EXPERIMENTAL
Intervention: both techniques
Number of subjects: 32
Study 2956427 — intervention group
Group type: EXPERIMENTAL
Intervention: High exercise (56% of maximum work capacity)
Number of subjects: 10
Study 2956427 — intervention group
Group type: COMPARATOR
Intervention: Low exercise (28% of maximum, simulating normal daytime activity)
Number of subjects: 10
Study 31146872 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 251
Study 31146872 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve repair
Number of subjects: 251
Study 31146872 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve surgery (both replacement and repair)
Number of subjects: 251
Study 29423513 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens treatment
Number of subjects: 57
Study 27183095 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) with donor lymphocyte infusion (DLI)
Number of subjects: 16
Study 27183095 — intervention group
Group type: COMPARATOR
Intervention: Brentuximab vedotin (BV) without donor lymphocyte infusion (DLI)
Number of subjects: 16
Study 27183095 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV)
Number of subjects: 16
Study 25326126 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (lap group)
Number of subjects: 47
Study 25326126 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (open group)
Number of subjects: 47
Study 22055966 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised home visit program by non-professional home rehabilitation assistants (HRAs) for 10-14 months
Number of subjects: 417
Study 22055966 — intervention group
Group type: COMPARATOR
Intervention: No home visit intervention (Control Group)
Number of subjects: 417
Study 20444845 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate zoledronic acid (ZOL; 4 mg every 6 months)
Number of subjects: 1065
Study 20444845 — intervention group
Group type: COMPARATOR
Intervention: Delayed zoledronic acid (initiated only for fracture or high risk thereof)
Number of subjects: 1065
Study 20444845 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate zoledronic acid (ZOL)
Number of subjects: 1065
Study 17880755 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for 5 days
Number of subjects: 192
Study 17880755 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days
Number of subjects: 192
Study 15270876 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 150 mg m(‐2) on days 1‐5 every 28 days + IFN‐alpha 2b 10 MIU m(‐2) every other day (Group A)
Number of subjects: 47
Study 15270876 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 150 mg m(‐2) on days 1‐5 every 28 days + IFN‐alpha 2b fixed dose of 10 MIU every other day (Group B)
Number of subjects: 47
Study 15270876 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with at least one complete remission
Number of subjects: 47
Study 15270876 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with at least one partial response
Number of subjects: 47
Study 15270876 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who completed at least three cycles of therapy with partial or complete response
Number of subjects: 47
Study 15270876 — intervention group
Group type: EXPERIMENTAL
Intervention: Major side effects of treatment
Number of subjects: 47
Study 11359431 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg inhaled plus 200 microg intranasal)
Number of subjects: 12
Study 11359431 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg oral)
Number of subjects: 12
Study 9217273 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ug/day of 1,25(OH)2D3 for 14 days
Number of subjects: 40
Study 9217273 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ug/day of 1,25(OH)2D3 for 14 days
Number of subjects: 40
Study 9217273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7954251 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented TPN (40 g L-alanyl-L-glutamine, 26 g glutamine)
Number of subjects: 20
Study 7954251 — intervention group
Group type: COMPARATOR
Intervention: Control TPN (without glutamine)
Number of subjects: 20
Study 3325090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 9
Study 29211298 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (3 courses)
Number of subjects: 432
Study 28375117 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoebex (400mg)
Number of subjects: 184
Study 28375117 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (400mg)
Number of subjects: 184
Study 25365012 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional meat (FM)
Number of subjects: 43
Study 25365012 — intervention group
Group type: COMPARATOR
Intervention: Control meat (CM)
Number of subjects: 43
Study 25365012 — intervention group
Group type: COMPARATOR
Intervention: Comparison between FM and CM
Number of subjects: 43
Study 23385035 — intervention group
Group type: EXPERIMENTAL
Intervention: IV rocuronium 0.06 mg/kg
Number of subjects: 260
Study 23385035 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 260
Study 20492571 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 6
Study 20492571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 18822334 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-534 vaccine
Number of subjects: 0
Study 16386671 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible patients (standard definition)
Number of subjects: 593
Study 16386671 — intervention group
Group type: COMPARATOR
Intervention: Noninducible patients
Number of subjects: 593
Study 16386671 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow inducibility definition
Number of subjects: 593
Study 16386671 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad inducibility definition
Number of subjects: 593